Weijing Sun is an Oncology physician affiliated with The University of Kansas Cancer Center. OpenAlex indexes 369 publications with 14,398 citations (h-index 50); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2650 Shawnee Mission Pkwy
Westwood, KS 662052003
Telephone
913-588-1227Provider last certified this registry record 18 Sept 2023.
Clinical trials
- Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
Sponsor: University of Kansas Medical Center
- Phase II Study of Irinotecan and Panitumumab
Sponsor: Weijing Sun, MD, FACP
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year202516 payments$27,191openpaymentsdata.cms.gov ↗
- BeOne Medicines USA, Inc.Program year20253 payments
- Gilead Sciences, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
32.4%Atypical Antipsychotic11.7%Olanzapine100%Part D≥20 patientsPhenothiazine8%Prochlorperazine Maleate100%Part D≥21 patients+ 2 more classes in this area
Metabolism & gastrointestinal
24.4%Serotonin-3 Receptor Antagonist15.4%Ondansetron Hcl100%Part D≥31 patientsAntidiarrheal microorganisms9%Creon100%Part D<11 patientsSensory organs
14.8%Corticosteroid14.8%Dexamethasone100%Part D≥32 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Joaquina Baranda, MD
The University of Kansas Cancer Center
Andrea Jewell, MD
The University of Kansas Cancer Center
Marc Hoffmann, MD
The University of Kansas Cancer Center
Haitham Abdelhakim, MBCHB
The University of Kansas Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”